Canadian Cancer Trials Group Bulletins


OV.21 and Ovarian Cancer Canada

The Canadian Cancer Trials Group and Ovarian Cancer Canada have teamed up to promote awareness of OV.21 -- A Phase II/III Trial of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant IV Chemotherapy.

The possible advantage of IP treatment is that since the chemotherapy drugs bathe the abdominal organs directly, it may provide a more effective way of killing the ovarian cancer cells residing there. Researchers are hopeful that this study will help to determine whether IP chemotherapy treatment is more effective than IV chemotherapy treatment.

OV.21 is recruiting participants from the United Kingdom, Spain, the United States and Canada, and we are hoping to increase awareness of the study across Canada to encourage more women diagnosed with ovarian cancer to participate.

The Canadian Cancer Trials Group is grateful to Ovarian Cancer Canada for promoting this trial!!

For the complete article, please use this link ...

If you have questions or would like more information about OV.21, please contact Chad Winch, Study Coordinator, at (613) 533-6430 or